In addition, among patients with cancer, identification of individuals with certain germline pathogenic variants is necessary for personalized cancer treatment such as PARP inhibitors for those with BRCA1/2 likely pathogenic or pathogenic variants and immune checkpoint therapies for those with Lynch syndrome [9, 10]. This evidence concerns the gene BRCA1 and cancer.